Lilly's Zepbound Breaks Ground with First U.S. Drug Approval for Sleep Apnea

Lilly's Zepbound Breaks Ground with First U.S. Drug Approval for Sleep Apnea
3 days ago

In a groundbreaking development for the treatment of sleep apnea, Eli Lilly and Company has secured its first drug approval with Zepbound, marking a significant milestone in the pharmaceutical landscape for addressing this common sleep disorder. This approval not only opens doors for more effective interventions but also raises hopes for millions suffering from the condition across the United States.

Continue reading
Eli Lilly's Mounjaro Misses Out on Dedicated Sleep Apnea Approval in Europe

Eli Lilly's Mounjaro Misses Out on Dedicated Sleep Apnea Approval in Europe
10 days ago

In a significant development for the pharmaceutical industry, Eli Lilly's diabetes drug, Mounjaro, has been denied a separate label for the treatment of sleep apnea in Europe. This decision, announced recently, highlights the ongoing complexities within the regulatory landscape governing medical treatments and their approvals across different markets.

Continue reading